Digestive cancer
Conditions
Interventions
Oral administration of Hangeshashinto 7.5g/day t.i.d. before meals.
No take Hangeshashinto.
Sponsors
Osaka Medical College Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with digestive cancer who undergo chemotherapy 2. Patients with oral mucositis caused by prior chemotherapy 3. ECOG Performance status : 0-1 4. Over 20 years old female 5. Patients who maintain main organs function 1) White blood cells count > 2,500/mm3 and < 12,000/mm3 2) Neutrophil count > 1,500/mm3 3) Platelet count > 10.0 X 10^4/mm3 4) AST,ALT > normal limit X 2.5 5) Serum total bilirubin < normal limit X 1.5 6) Serum creatinine < normal limit 6. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients who receives a medical prescription of herbal medicine within 2 weeks before registration of the final examination 2. Patients with the past of severe medicine hyperesthesia or severe drug allergy 3. Anti-inflammation anodyne medicine, OPIOIDO or the patient who has a medical treatment by a steroid 4.Sense unusualness or perception, some incomplete patients 5. Patients with active double cancer 6. Patients with serious heart diseases 7. Patients with serious lung diseases 8. Patients with serious constipation 9. Pregnant woman, lactating woman and patient with a possibility of the pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DTM:Duration time of oral mucositis for 21 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of oral mucostis, Incidence of diarrhea, Blood level of CRP, Change of body weight and blood level of albumin | — |
Countries
Japan
Contacts
Public ContactTakayuki Kii
Osaka Medical College Hospital Cancer Chemotherapy Center
Outcome results
None listed